{"filing":{"accession_number":"0001437749-26-028778","cik":"0000925741","ticker":"BCDA","company_name":"BioCardia, Inc.","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-24","primary_document":"bcda20260821_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774926028778/bcda20260821_8k.htm"},"events":[{"id":29074,"run_id":26603,"accession_number":"0001437749-26-028778","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"BioCardia announced FDA confirmation of meeting minutes supporting a follow-on De Novo pre-submission for its Helix Transendocardial Delivery Catheter. This is a regulatory milestone—the FDA's acceptance of pre-submission meeting minutes—that advances the company's pathway toward device approval. While not a final approval or a specific operational contract, this represents material progress on a key product platform that the company intends to leverage for commercial partnerships. The event is clearly operational/regulatory in nature but does not fit the specific categories of earnings, M\u0026A, litigation, or other named types.","company_name":"BioCardia, Inc.","ticker":"BCDA","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31229,"accession_number":"0001437749-26-028778","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BioCardia announced FDA confirmation of meeting minutes supporting a follow-on De Novo pre-submission for its Helix Transendocardial Delivery Catheter. This is a regulatory milestone—the FDA's acceptance of pre-submission meeting minutes—that advances the company's pathway toward device approval. While not a final approval or a specific operational contract, this represents material progress on a key product platform that the company intends to leverage for commercial partnerships. The event is clearly operational/regulatory in nature but does not fit the specific categories of earnings, M\u0026A, litigation, or other named types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:31:37.943859+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31229,"accession_number":"0001437749-26-028778","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BioCardia announced FDA confirmation of meeting minutes supporting a follow-on De Novo pre-submission for its Helix Transendocardial Delivery Catheter. This is a regulatory milestone—the FDA's acceptance of pre-submission meeting minutes—that advances the company's pathway toward device approval. While not a final approval or a specific operational contract, this represents material progress on a key product platform that the company intends to leverage for commercial partnerships. The event is clearly operational/regulatory in nature but does not fit the specific categories of earnings, M\u0026A, litigation, or other named types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:31:37.943859+00:00","company_name":"BioCardia, Inc.","ticker":"BCDA","filing_date":"2026-08-24"}]}